Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial

2018 Genitourinary Cancers Symposium

Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk, in a subgroup analysis of progression-free survival and objective response rates (Abstract 582).

Aug

Today In Oncology

FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

Issues in Doctor-Patient Discussions on Potential Harms of Lung Cancer Screening

VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer

Basal Cell Carcinoma and Risk for Development of Other Cancers

Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting

;